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Abstract
Background: Experimental studies have revealed that green tea catechins and theanine prevent influenza
infection, while the clinical evidence has been inconclusive. This study was conducted to determine whether
taking green tea catechins and theanine can clinically prevent influenza infection.
Methods: Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial of 200
healthcare workers conducted for 5 months from November 9, 2009 to April 8, 2010 in three healthcare facilities
for the elderly in Higashimurayama, Japan.
Interventions: The catechin/theanine group received capsules including green tea catechins (378 mg/day) and
theanine (210 mg/day). The control group received placebo.
Main Outcome Measures: The primary outcome was the incidence of clinically defined influenza infection.
Secondary outcomes were (1) laboratory-confirmed influenza with viral antigen measured by
immunochromatographic assay and (2) the time for which the patient was free from clinically defined influenza
infection, i.e., the period between the start of intervention and the first diagnosis of influenza infection, based on
clinically defined influenza infection.
Results: Eligible healthcare workers (n = 197) were enrolled and randomly assigned to an intervention; 98
were allocated to receive catechin/theanine capsules and 99 to placebo. The incidence of clinically defined
influenza infection was significantly lower in the catechin/theanine group (4 participants; 4.1%) compared with
the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022). The incidence
of laboratory-confirmed influenza infection was also lower in the catechin/theanine group (1 participant; 1.0%)
than in the placebo group (5 participants; 5.1%), but this difference was not significant (adjusted OR, 0.17;
95% CI, 0.01 to 1.10; P = 0.112). The time for which the patient was free from clinically defined influenza
infection was significantly different between the two groups (adjusted HR, 0.27; 95% CI, 0.09 to 0.84;
P = 0.023).
Conclusions: Among healthcare workers for the elderly, taking green tea catechins and theanine may be effective
prophylaxis for influenza infection.
Trial Registration: ClinicalTrials (NCT): NCT01008020
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Background
Influenza infection is the principal cause of acute
respiratory illnesses and occurs in epidemics worldwide,
in all ages [1]. To reduce morbidity and mortality, a
variety of public health interventions have been imple-
mented, including facemasks, gargling, improved hand
hygiene and coughing etiquette [2-5]. Vaccines are the
most widely used intervention for influenza infection
prophylaxis, but their effectiveness depends on the type
of influenza virus involved in each season’s epidemic,
and they also have the drawback of limited supply [6].
Thus far, evidence supporting the effectiveness of anti-
virals such as amantadine or neuraminidase inhibitors
has not been well established [7]. Therefore, it is impor-
tant to find other ways to reduce the prevalence of
influenza infection.
The use of catechins and theanine, which are well-
known components of green tea, shows promise as an
intervention for preventing influenza infection [8].
Experimental studies have revealed that green tea cate-
chins can prevent influenza infection in vitro, but clini-
cal evidence has so far been inconclusive [9]. Recently,
in a small prospective cohort study, we reported that
gargling with tea catechin extracts was effective in pre-
venting influenza infection in elderly nursing home resi-
dents [10]. The consumption of tea extracts including
catechins and theanine has also been reported to
enhance systemic immunity and prevent the occurrence
of upper respiratory tract infection and influenza symp-
toms in healthy adults [11]. Based on these findings, we
designed a randomized, double-blind study to evaluate
the clinical efficacy of green tea catechins and theanine
in preventing influenza infection.
Methods
Study Design
A randomized, double-blind, 2-group parallel study was
conducted to compare the effects of green tea catechins
and theanine (catechin/theanine) capsules with those of
placebo on the prevention of influenza for 5 months
during the influenza season, from November 9, 2009 to
April 8, 2010. We enrolled adult (over 20 years of age)
healthcare workers who worked in 3 healthcare facilities
for the elderly in Higashimurayama, Japan. Participants
were excluded for the following criteria: tea allergy; his-
tory of influenza infection within 6 months before or
24 hours after entering the study; use of any medication
or supplement affecting respiratory tract infections;
immune disease; severe cardiac, respiratory, renal, or
hepatic dysfunction; anemia requiring treatment; preg-
nancy or lactation.
The participants completed a self-administered ques-
tionnaire to assess baseline characteristics including age,
sex, body mass index (BMI), smoking and alcohol
consumption, and vaccination for the influenza virus.
Their tea consumption habits before intervention were
also determined, and any tea beverage such as black,
green, oolong, or herbal tea intake was restricted to less
than 250 mL per day over the entire course of the study.
Eligible participants were randomized by a computer-
generated block randomization schema. Participants
were provided with coded aluminum bags containing
catechin/theanine capsules or placebo identical in
appearance and taste in a double-blind manner. The
participants were asked to take 6 capsules per day, con-
taining a total of 378 mg catechins (including 270 mg
(-)-epigallocatechin gallate) (THEA-FLAN 90S, ITO EN,
Ltd., Tokyo, Japan) and 210 mg theanine (Suntheanine®,
Taiyo Kagaku Co., Ltd., Mie, Japan) or placebo. The
participants were asked to complete a questionnaire
concerning the occurrence of influenza infection, pre-
ventive measures for maintaining hygiene, any adverse
event, and their daily adherence to taking the capsules.
The questionnaires were collected monthly, and careful
safety monitoring was conducted throughout the study.
Each participant was observed for the same time.
All participants gave written informed consent before
entering the study. The study protocol was approved by
the ethics committee at the University of Shizuoka and
was conducted in accordance with the Declaration of
Helsinki.
Outcomes
The primary outcome was the incidence of clinically
defined influenza infection. The doctor diagnosed clini-
cally defined influenza on the basis of fever (tempera-
ture, ≥37.8°C) and any 2 of the following clinical
symptoms: cough, sore throat, headache, or myalgia
[12]. The secondary outcomes were (1) the incidence of
laboratory-confirmed influenza infection with viral anti-
gen measured by immunochromatographic assay (Rapid-
Testa® FLUII, Sekisui Medical Co., Ltd., Tokyo, Japan)
and (2) the time for which the patient was free from
clinically defined influenza infection, i.e., the period
between the start of the intervention and the first diag-
nosis of influenza infection. The antigen test was per-
formed for all participants with suspected influenza
infection, including clinically defined influenza. The
antigen test, with a nasopharyngeal swab specimen, was
approximately 85% sensitive and 100% specific for the
influenza virus type A and B antigens [10,13].
Statistical Analyses
In consideration of our previous study in the aged-group
participants, we estimated that the primary outcome would
occur in 1% of participants in the catechin/theanine group
and 11% of those in the placebo group [10]. The sample
size was calculated as 88 for each group at a power level of
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0.80 and a 2-sided a level of 0.05. With an estimated 10%
dropout rate, we set the total sample size at 194.
All efficacy and safety analyses were performed accord-
ing to the intention-to-treat principle. We used Fisher’s
exact test for categorical comparisons of the data. Differ-
ences in the mean values of continuous measurements
were tested by Student’s t test or Wilcoxon rank sum
test. Multiple logistic regression analysis was used to pro-
vide adjusted odds ratio (OR) estimates and 95% confi-
dence interval (CI) for association between catechin/
theanine capsules and the incidence of influenza infec-
tion. Cumulative incidence rates were determined by the
Kaplan-Meier method. The Cox proportional hazards
regression model was used to evaluate the association
between catechin/theanine capsules and the time for
which the patient was free from clinically defined influ-
enza infection, adjusted for potential confounding vari-
ables after confirmation of the proportional hazard
assumptions. The cases taken the influenza-free time to
be censored were the occurrence of primary outcome
and discontinuation. Among baseline characteristics,
those with P < 0.20 were considered potential confound-
ing variables. They were defined on multiple logistic
regression analysis and transferred to the Cox propor-
tional hazard model. In these multivariable analyses, we
also added age as a significant explanatory variable.
200 Volunteers assessed for eligibility
98 Randomized to receive 
     catechin/theanine
97 Received catechin/theanine 
     as randomized
1 Did not receive intervention 
   (influenza infection within 24
   hours)
99 Randomized to receive 
     placebo
99 Received placebo 
     as randomized
7 Discontinued
4 Had adverse events
3 Transferred
10 Discontinued
5 Had adverse events
3 Transferred
2 Resigned
97 Included in analysis
1 Excluded (withdrew prior to
   follow-up)





Figure 1 Flow diagram for trial of catechin/theanine vs. placebo.
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The threshold for statistical significance was set at P <
0.05. Analyses were conducted using R version 2.11.1
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Of 200 participants recruited and assessed for eligibility, 3
were excluded according to the exclusion criteria (2, his-
tory of influenza infection within 6 months; 1, pregnancy).
The remaining 197 participants were enrolled and ran-
domly assigned to an intervention; 98 were allocated to
the catechin/theanine group and 99 to the placebo group
(Figure 1). After assignment, 1 participant in the catechin/
theanine group was excluded according to the exclusion
criteria (influenza infection within 24 hours after entering
the study). Adherence to the test capsules was 93.2% in
the catechin/theanine group and 91.9% in the placebo
group.
The baseline characteristics of the participants are
shown in Table 1. The mean age of participants was
42.7 years and uniformly distributed. Study groups were
well balanced in terms of baseline characteristics except
for BMI (P = 0.010). Therefore, BMI was considered as a
potential confounding variable and was included in the
variables of multivariate analyses. During the study, clini-
cally defined influenza infection occurred in a total of 17
participants (8.7%), 6 of whom (3.1%) were laboratory con-
firmed with the type A antigen. No participants had more
than one influenza infection during the observation time.
In the univariate comparison between the incidence of
clinically defined influenza infections and baseline char-
acteristics, age was the only significant variable and
younger age was correlated with the high incidence of
influenza infection (P = 0.027). Significant associations
were not found among other variables such as sex, vac-
cination, preventive measures for maintaining hygiene
(i.e., hand washing, facemask application, and gargling),
smoking, and alcohol and tea consumption.
The incidence of clinically defined influenza infections
was significantly lower in the catechin/theanine group
(4 participants; 4.1%) than in the placebo group (13 par-
ticipants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to
0.76, P = 0.022). The incidence of laboratory-confirmed
influenza infection was also lower in the catechin/thea-
nine group (1 participant; 1.0%) than in the placebo
group (5 participants; 5.1%), but this difference was
not significant (adjusted OR, 0.17; 95% CI, 0.01 to 1.10;
P = 0.112).
Kaplan-Meier curves were shown in Figure 2. The
time for which the patient was free from clinically
defined influenza infection, estimated with the Cox
Table 1 Baseline characteristics of study participants
Catechin/Theanine group Placebo group
Characteristics (n = 97) (n = 99) P Value
Age, mean (SD) [range], y 42.1 (12.4) [21-65] 43.2 (13.1) [22-69] 0.63a
Sex, No. (%)
Male 21 (21.6) 23 (23.2)
Female 76 (78.4) 76 (76.8) 0.86b
BMI, mean (SD) [range] 21.6 (2.8) [15.9-30.9] 22.7 (3.2) [16.6-33.3] 0.01c
Vaccination for influenza virus, No. (%) 91 (93.8) 91 (91.9) > 0.99b
Hand-washingd, No. (%) 72 (74.2) 72 (72.7) 0.87b
Facemasksd, No. (%) 15 (15.5) 20 (20.2) 0.46b
Garglingd, No. (%) 71 (73.2) 68 (68.7) 0.53b
Smoking, No. (%)
Yes 29 (29.9) 29 (29.3)
Past 15 (15.5) 15 (15.2) > 0.99b
No 53 (54.6) 55 (55.6)
Alcohol consumption, No. (%)
Yes 49 (50.5) 56 (56.6)
Past 3 (3.1) 4 (4.0) 0.66b
No 45 (46.4) 39 (39.4)
Tea consumption, mean (SD), mL/day 494.3 (415.6) 481.3 (374.3) 0.95a
Abbreviation: BMI, body mass index.
aP value based on Wilcoxon rank sum test.
bP value based on Fisher’s exact test.
cP value based on Student’s t test.
dThe preventive measures such as hand-washing, facemask application, or gargling was performed 4 days per week or more during the study period.
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Figure 2 Kaplan-Meier curves of clinically defined influenza.
Table 2 Results of multiple logistic regression analysis and Cox proportional hazards regression model
Laboratory confirmed influenzaa Clinically defined influenzab
Variables OR (95% CI)c P Valuec OR (95% CI)c P Valuec HR (95% CI)d P Valued
Allocation
Catechin/Theanine 0.17 (0.01 to 1.10) 0.11 0.25 (0.07 to 0.76) 0.02 0.27 (0.09 to 0.84) 0.02
Placebo 1 [Reference] 1 [Reference] 1 [Reference]
Age 0.98 (0.91 to 1.04) 0.48 0.95 (0.91 to 0.99) 0.03 0.96 (0.92 to 1.00) 0.04
BMI 0.89 (0.63 to 1.16) 0.43 0.95 (0.79 to 1.11) 0.53 0.97 (0.83 to 1.13) 0.66
Abbreviations: OR, odds ratio; CI, confidence interval; HR, hazard ratio; BMI, body mass index.
aLaboratory-confirmed influenza infection with viral antigen detected by immunochromatographic assay.
bClinically defined influenza was diagnosed as fever (temperature, ≥37.8°C) and any 2 of the following clinical symptoms: cough, sore throat, headache, or
myalgia.
cOR and P values were estimated using multiple logistic regression.
dHR and P values were estimated using the Cox proportional hazards regression model.
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proportional hazards regression model, was significantly
different between the two groups (adjusted hazard ratio,
0.27; 95% CI, 0.09 to 0.84; P = 0.023) (Table 2). No ser-
ious adverse events were observed during the study.
Digestive symptoms such as bloating and constipation
occurred in both groups and were reported by 9.2% of
all participants. These symptoms were relativity mild
and did not significantly differ between the two groups.
Discussion and Conclusion
This randomized, double-blind, placebo-controlled trial
was conducted to determine whether taking green tea
catechins and theanine could clinically prevent influenza
infection. We found that consuming catechin/theanine for
5 months had a statistically significant preventive effect on
clinically defined influenza infection and was well toler-
ated. To our knowledge, this is the first randomized clini-
cal trial to evaluate the efficacy of green tea catechins and
theanine in the prevention of influenza infection.
Experimental studies have shown some mechanisms of
the action of green tea catechins and theanine on the
prevention of influenza infection. These studies have
shown that green tea catechins bind to the hemaggluti-
nin molecule of influenza virus, thereby inhibiting the
virus adsorption to the host cells and blocking virus
assembly or maturation cleavage [14-16]. Theanine has
a possibility to enhance the systemic immunity (gδ T-
cell function) for influenza infection [11]. Our results
seem to provide clinical evidence to confirm these biolo-
gical activities.
Contrary to worldwide prevalence in the 2009 novel
influenza virus A (H1N1) pandemic, laboratory-confirmed
influenza infection occurred in only 3.1% of the study
participants. Probably in part due to this small sample
size, the incidence of laboratory-confirmed influenza was
not significantly different in the catechin/theanine group,
in spite of showing a decreased tendency compared to
placebo. Moreover, the participants were healthcare
workers with a high rate (92.9%) of vaccination; therefore
the effectiveness of catechin/theanine might be underesti-
mated. Additional large-scale randomized trials are
needed to confirm the effectiveness of catechin/theanine
as prophylaxis for laboratory-confirmed influenza
infection.
Abbreviations
OR: odds ratio; CI: confidence interval; HR: hazard ratio.
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